Association between chemotherapy and plasma adipokines in patients with colorectal cancer

Słomian, Grzegorz; Świętochowska, Elżbieta; Malinowska-Borowska, Jolanta; Kasperczyk, Sławomir; Rogalska, Anna; Nowak, Przemysław

doi:10.1016/j.pharep.2014.05.015

Cited by 17 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although beyond the scope of this study, Karapanagiotou et al (62) revealed a lack of prognostic value for the assessed adipokines in patients with advanced NSCLC. Concordant with these findings, a recent study by Slomian et al (63) revealed a significant increase in circulating levels of leptin and adiponectin in a cohort of patients with advanced colorectal cancer who required palliative chemotherapy.…”

Section: Hgf Pg/mlsupporting

confidence: 62%

Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics

et al. 2017

View full text Add to dashboard Cite

Abstract. The development and progression of cancer is a complex and multifactorial process and the global prevalence of obesity is markedly increasing. A number of studies have made an association between obesity and increased rates of epithelial tumors. Obesity is associated with altered adipokine levels, potentially contributing to the process of tumor development and metastasis. In the current study, the associations between circulating adipokines and measures of adiposity and tumor characteristics among patients diagnosed with solid malignancies were examined at the time of presentation, and following the administration of chemotherapy. A total of 30 patients with cancer and matched healthy controls were enrolled in the present study. Plasma adipokine levels of hepatocyte growth factor (HGF), adiponectin and leptin were determined using commercially available ELISA kits. At baseline, plasma HGF, adiponectin and leptin levels were not significantly different between patients with cancer and the healthy controls. Circulating HGF levels were significantly associated with the stage of cancer at diagnosis (P=0.044), but lacked a significant association with lymph node status (P=0.194). Plasma adiponectin and leptin levels were not significantly associated with tumor characteristics at the time of diagnosis. Only leptin was positively correlated with the body mass index of patients with cancer (P<0.001). No significant correlations were detected between the evaluated adipokines and measures of visceral obesity, as determined by waist circumference and the waist-hip ratio at presentation. Following administration of chemotherapy, adiponectin was the only adipokine evaluated in the current study that exhibited a significant difference, when compared with baseline plasma levels (P= 0.013), and a significant positive correlation between baseline and follow-up circulating levels (P=0.002) among patients with cancer. In addition, there were no significant inter-correlations between circulating adipokines at baseline level and during follow-up in patients with cancer. Collectively, the findings of the current study suggest a lack of diagnostic roles for the adipokines investigated and no significant association with measures of adiposity. Adiponectin may be a potential adipokine to measure in patients with cancer, in order to further assess its prognostic and predictive potential. IntroductionCancer is a major public health problem and is a leading cause of mortality worldwide (1). Annual cancer cases are predicted to rise from 14 million in 2012 to 22 million within the next two decades (2). In Jordan, there has been a notable increase in the incidence and burden of cancer and, according to the most recent report from the Jordan National Cancer Registry, the number of new cancer cases diagnosed among Jordanians increased by ~46% from 2000-2012 (3). The most common types of cancer among Jordanian patients were breast, colorectal, lung, lymphoma and urinary bladder cancer (3). At present, epidemiological and experimental...

show abstract

Section: Hgf Pg/mlsupporting

confidence: 62%

Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Indeed, in vitro , visfatin leads to increased cancer cell survival and migration [29], the preferentially stimulated proliferation of HCC cells [18], and the increased viability of the cancer cells by inducing antioxidative activity [30]. In vivo , the visfatin levels decreased significantly after chemotherapy [31]. On the basis of previous studies and our results, visfatin could be a potential therapeutic target of HCC.…”

Section: Discussionmentioning

confidence: 57%

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Sun

Zhu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels of visfatin of 135 HCC patients, 115 chronic hepatitis B (CHB) patients, 129 liver cirrhosis (LC) patients, and 149 healthy controls were determined via enzyme-linked immunosorbent assay. Meanwhile, serum alpha fetal protein (AFP) and interleukin-6 (IL-6) were also assayed. The median serum visfatin concentration in HCC patients was 1.113 ng/ mL (range: 0.823-2.214 ng/mL), which was significant higher than those of healthy controls, CHB patients, and LC patients (P<0.05). The serum visfatin concentration in HCC patients was positively correlated with AFP (r=0.595, P<0.001) and IL-6 (r=0.261, P<0.015) and was also associated with tumor size and tumor node metastasis stage. Moreover, elevated levels of serum visfatin were associated with a higher HCC risk for CHB and LC patients. Multivariate Cox regression analysis had shown that HCC patients with high levels of serum visfatin had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). Using a cutoff visfatin level of 1.403 ng/mL, the receiver operating characteristic curve analysis showed unappealing sensitivity and specificity values (45.76% and 74.79%, respectively; AUC=0.626) regarding visfatin's use as a diagnostic marker for HCC. Our results indicate that increased serum visfatin levels are associated with poor prognosis of HCC. Visfatin may be a potential therapeutic target of HCC.

show abstract

“…Visfatin, which is secreted by visceral fat, is a new adipokine that is structurally identical to pre-B-cell colony-enhancing factor (PBEF) and exhibits nicotinamide phosphoribosyltransferase (NAMPT) enzymatic activity (Dalamaga et al, 2012;Tulubas et al, 2013) Elevated circulating levels of visfatin have been found in patients with metabolic disorders, such as diabetes mellitus, obesity or metabolic syndrome (MS), which might be related to the development of MS-related cancers (Słomian et al, 2014) So, in this study we aimed to evaluate the levels of (Adiponectin, Resistin and Visfatin) in pre-malignant and malignant colorectal lesions for early detection to understand the possible role of adipocytokines in relation to disease progression and early detection of colorectal cancer.…”

Section: Circulating Levels Of Adipocytokines As Potential Biomarkersmentioning

confidence: 99%

Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients

Zekri¹,

Bakr²,

Ezzat³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Early detection of various kinds of cancers nowadays is needed including colorectal cancer due to the highly significant effects in improving cancer treatment. The aim of this study was to evaluate the potential value of adiponectin, visfatin and resistin as early biomarkers for colorectal cancer patients. Materials and Methods: Serum levels of adiponectin, visfatin and resistin were measured by a sandwich-enzyme-linked (ELISA) assay technique in 114 serum samples comprising 34 patients with colorectal cancer (CRC), 27 with colonic polyps (CP), 24 with inflammatory bowel disease (IBD) and 29 healthy controls .The diagnostic accuracy of each serum marker was evaluated using receiver-operating characteristic (ROC) curve analysis. Results: The mean concentration of adiponectin was significantly higher in CRC and CP groups than IBD and control groups (P-value <0.05). Also the mean concentration of serum resistin was significantly elevated in the IBD and control groups compared to CRC and CP groups (P-value = 0.014). However, no significant difference was noted in patients of the CRC and CP groups. On the other hand, the mean concentration of visfatin was significantly elevated in CRC and control groups compared to CP and IBD groups (P-value = 0.03). ROC analysis curves for the studied markers revealed that between CRC and IBD groups serum level of adiponectin had a sensitivity of 76.7% and a specificity of 76% at a cut off value of 3940, +LR being 3.

show abstract

Association between chemotherapy and plasma adipokines in patients with colorectal cancer

Cited by 17 publications

References 30 publications

Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics

Analysis of circulating adipokines in patients newly diagnosed with solid cancer: Associations with measures of adiposity and tumor characteristics

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients

Contact Info

Product

Resources

About